Cervical dissecting extravasation of oxaliplatin: A case report

Hernando,Jorge; Riera‑Arnau,Judit; Roca,Maria; Garcia,Alejandro; Capdevila,Jaume

doi:10.3892/mco.2022.2493

Cervical dissecting extravasation of oxaliplatin: A case report

Authors:
- Jorge Hernando
- Judit Riera‑Arnau
- Maria Roca
- Alejandro Garcia
- Jaume Capdevila
View Affiliations

Affiliations: Gastrointestinal and Endocrine Tumors Unit, Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Autonomous University of Barcelona, 08035 Barcelona, Spain, Clinical Pharmacology Service, Department of Pharmacovigilance and Pharmacoepidemiology, Vall d'Hebron University Hospital, Autonomous University of Barcelona, 08035 Barcelona, Spain
Published online on: January 12, 2022 https://doi.org/10.3892/mco.2022.2493
Article Number: 60

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oxaliplatin is a chemotherapy drug considered to be an irritant and vesicant. Peripheral extravasation could happen following oxaliplatin chemotherapy administration, but mediastinal or cervical events are rare. The present study focused on the case of a 64‑year‑old female patient with KRAS‑mutated colorectal adenocarcinoma. The patient was prescribed folinic acid, fluorouracil and oxaliplatin chemotherapy via a subcutaneous pump or port‑a‑cath device, which was inserted into the right subclavian vein. The patient reported a sudden throbbing pain in the chest wall and anterior cervical region. After performing a computed tomography scan, anterior cervical collection and jugular‑subclavian venous confluence at the distal end was observed at the venous access site of the subcutaneous port‑a‑cath device, which extended cranially, dissected cervical planes and forming a hydro‑aerial collection in the submaxillary region. Subsequently, the port‑a‑cath device was removed and a warm dry compress was applied. After 2 weeks, the patient had fully recovered without any sequelae at the cervical level. To the best of the authors' knowledge, this is the first case of cervical extravasation of oxaliplatin reported in the literature to date and will help to manage similar situations.

View Figures

View References

1	Yuan X, Zhang W, He Y, Yuan J, Song D, Chen H, Qin W, Qian X, Yu H and Guo Z: Proteomic analysis of cisplatin- and oxaliplatin-induced phosphorylation in proteins bound to Pt-DNA adducts. Metallomics. 12:1834–1840. 2020.PubMed/NCBI View Article : Google Scholar
2	Spanish Agency for Medicines and Health Products (AEMPS): Technical datasheet of oxaliplatin. AEMPS, Madrid, 2021. https://cima.aemps.es/cima/publico.html. Accessed January 22, 2021.
3	Goodsell DS: The molecular perspective: Cisplatin. Oncologist. 11:316–317. 2006.PubMed/NCBI View Article : Google Scholar
4	Bahadori F and Demiray M: Management of extravasation of oxaliplatin by mimicking its biotransformation. Clin Transl Oncol. 20:1353–1357. 2018.PubMed/NCBI View Article : Google Scholar
5	Baur M, Kienzer HR, Rath T and Dittrich C: Extravasation of oxaliplatin (Eloxatin((R)))-clinical course. Onkologi. 23:468–471. 2000.PubMed/NCBI View Article : Google Scholar
6	Pérez Fidalgo JA, García Fabregat L, Cervantes A, Margulies A, Vidall C and Roila F: ESMO Guidelines Working Group. Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines. Ann Oncol. 23 (Suppl 7):vii167–vii173. 2012.PubMed/NCBI View Article : Google Scholar
7	Pericay C, López A, Soler JR, Bonfill T, Dotor E and Saigí E: Extravasation of oxaliplatin: An infrequent and irritant toxicity. Clin Transl Oncol. 11:114–116. 2009.PubMed/NCBI View Article : Google Scholar
8	Wickham R, Engelking C, Sauerland C and Corbi D: Vesicant extravasation part II: Evidence-based management and continuing controversies. Oncol Nurs Forum. 33:1143–1150. 2006.PubMed/NCBI View Article : Google Scholar
9	Kreidieh FY, Moukadem HA and El Saghir NS: Overview, prevention and management of chemotherapy extravasation. World J Clin Oncol. 7:87–97. 2016.PubMed/NCBI View Article : Google Scholar
10	Narducci F, Jean-Laurent M, Boulanger L, El Bédoui S, Mallet Y, Houpeau JL, Hamdani A, Penel N and Fournier C: Totally implantable venous access port systems and risk factors for complications: A one-year prospective study in a cancer centre. Eur J Surg Oncol. 37:913–918. 2011.PubMed/NCBI View Article : Google Scholar
11	Masters B, Hickish T and Cidon EU: A midline for oxaliplatin infusion: The myth of safety devices. BMJ Case Rep. 2014(bcr2014204360)2014.PubMed/NCBI View Article : Google Scholar
12	Boesen C and Nielsen SE: Reversible tissue damage after paravasal infusion of oxaliplatin. Ugeskr Laeger. 177(V07140390)2015.PubMed/NCBI(In Danish).
13	Leon-Ferre RA, Abu Hejleh TB and Halfdanarson TR: Extravasation of oxaliplatin into the mediastinum: A case report and review of the literature. Clin Adv Hematol Oncol. 10:546–548. 2012.PubMed/NCBI
14	Haslik W, Hacker S, Felberbauer FX, Thallinger C, Bartsch R, Kornauth C, Deutschmann C and Mader RM: Port-a-Cath extravasation of vesicant cytotoxics: Surgical options for a rare complication of cancer chemotherapy. Eur J Surg Oncol. 41:378–385. 2015.PubMed/NCBI View Article : Google Scholar
15	Azaïs H, Bresson L, Bassil A, Katdare N, Merlot B, Houpeau JL, El Bedoui S, Meurant JP, Tresch E and Narducci F: Chemotherapy drug extravasation in totally implantable venous access port systems: How effective is early surgical lavage? J Vasc Access. 16:31–37. 2015.PubMed/NCBI View Article : Google Scholar
16	Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L and Saif MW: Hypersensitivity reactions associated with platinum antineoplastic agents: A systematic review. Met Based Drugs. 2010(207084)2010.PubMed/NCBI View Article : Google Scholar
17	Sorich J, Taubes B, Wagner A and Hochster H: Oxaliplatin: Practical guidelines for administration. Clin J Oncol Nurs. 8:251–256. 2004.PubMed/NCBI View Article : Google Scholar
18	Markman M: Toxicities of the platinum antineoplastic agents. Expert Opin Drug Saf. 2:597–607. 2003.PubMed/NCBI View Article : Google Scholar
19	de Lemos ML and Walisser S: Management of extravasation of oxaliplatin. J Oncol Pharm Pract. 11:159–162. 2005.PubMed/NCBI View Article : Google Scholar
20	Kretzschmar A, Pink D, Thuss-Patience P, Dörken B, Reichert P and Eckert R: Extravasations of oxaliplatin. J Clin Oncol. 21:4068–4069. 2003.PubMed/NCBI View Article : Google Scholar
21	Foo KF, Michael M, Toner G and Zalcberg J: A case report of oxaliplatin extravasation. Ann Oncol. 14:961–962. 2003.PubMed/NCBI View Article : Google Scholar
22	Conde-Estévez D and Mateu-de Antonio J: Update in the management of extravasations of cytocytostatic agent. Farm Hosp. 36:34–42. 2012.PubMed/NCBI View Article : Google Scholar : (In Spanish).